NASDAQ · Financial Statements

Avadel Pharmaceuticals plc (AVDL) Financial Statements

$21.64 NASDAQ: AVDL Market Cap $2.12B

Avadel Pharmaceuticals plc most recently reported annual revenue of $169.0M, a net loss of $49.0M. Revenue grew at an average annual rate of 23.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Avadel Pharmaceuticals plc: Revenue fell from $173.0M in 2015 to $169.0M in 2024, a change of -2.3% over 9 years; net profit was positive in 3 of 10 reported years; operating margin moved from 41.3% to -25.1%, a shift of -66.3 percentage points; the most recent year shows a net loss of $49.0M.

Income Statement — 10 Years (USD millions)

Metric2015201620172018201920202021202220232024
Revenue$173.0M$150.0M$173.0M$103.0M$59.0M$22.0M$0$0$28.0M$169.0M
Operating Expenses$102.0M$155.0M$84.0M$208.0M$83.0M$17.0M$86.0M$99.0M$166.0M$212.0M
Operating Profit$71.0M$-5.0M$88.0M$-105.0M$-24.0M$6.0M$-86.0M$-99.0M$-138.0M$-42.0M
Operating Margin41.3%-3.3%51.1%-101.6%-40.7%26.0%0.0%0.0%-493.0%-25.1%
Other Income$6.0M$-5.0M$3.0M$-8.0M$-14.0M$-11.0M$-8.0M$-13.0M$-23.0M$-7.0M
Interest$6.0M$1.0M$1.0M$11.0M$12.0M$13.0M$10.0M$12.0M$10.0M$11.0M
Depreciation$13.0M$14.0M$5.0M$7.0M$2.0M$2.0M$1.0M$1.0M$2.0M$3.0M
Profit Before Tax$78.0M$-10.0M$91.0M$-113.0M$-39.0M$-5.0M$-93.0M$-111.0M$-161.0M$-49.0M
Tax$48.1M$-324.7M$26.5M$15.8M$13.9M$238.3M$17.0M$-23.4M$310,000$500,000
Net Profit$41.0M$-41.0M$67.0M$-95.0M$-33.0M$7.0M$-77.0M$-137.0M$-160.0M$-49.0M
EPS$0.93$-1.00$1.61$-2.55$-0.89$0.13$-1.32$-2.29$-2.00$-0.51
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '22Mar '23Jun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25
Revenue$0$0$1.0M$7.0M$19.0M$27.0M$42.0M$50.0M$50.0M$53.0M$68.0M$77.0M
Operating Expenses$23.0M$28.0M$51.0M$42.0M$44.0M$53.0M$54.0M$50.0M$54.0M$56.0M$59.0M$76.0M
Operating Profit$-23.0M$-28.0M$-50.0M$-35.0M$-25.0M$-26.0M$-13.0M$0$-3.0M$-3.0M$9.0M$2.0M
Operating Margin0.0%0.0%-3311.6%-500.6%-128.0%-95.8%-30.7%-0.7%-6.5%-5.7%13.0%2.5%
Interest$3.0M$3.0M$2.0M$2.0M$2.0M$3.0M$3.0M$3.0M$3.0M$2.0M$2.0M$2.0M
Profit Before Tax$-27.0M$-31.0M$-64.0M$-36.0M$-29.0M$-27.0M$-14.0M$-3.0M$-5.0M$-5.0M$6.0M$0
Tax$-310,000$1.9M$-140,000$-250,000$350,000$-340,000$3.5M$-3.5M$-1.6M$-1.6M$-48.8M$63.0M
Net Profit$-27.0M$-31.0M$-64.0M$-36.0M$-29.0M$-27.0M$-14.0M$-3.0M$-5.0M$-5.0M$10.0M$0
EPS$-0.43$-0.48$-0.83$-0.41$-0.33$-0.30$-0.14$-0.03$-0.05$-0.05$0.10$0.00

Over the 10 years reported for Avadel Pharmaceuticals plc, borrowings increased from $1.0M in 2015 to $2.0M in 2024, cash stood at $51.0M in the latest year, shareholders' equity was $1.0M, current assets covered current liabilities 2.73 times.

Balance Sheet — 10 Years (USD millions)

Metric2015201620172018201920202021202220232024
Total Assets$215.0M$245.0M$252.0M$190.0M$151.0M$312.0M$247.0M$133.0M$165.0M$164.0M
Current Assets$166.0M$181.0M$124.0M$125.0M$82.0M$263.0M$192.0M$101.0M$134.0M$134.0M
Cash$65.0M$39.0M$17.0M$9.0M$10.0M$72.0M$51.0M$74.0M$31.0M$51.0M
Inventory$4.0M$3.0M$6.0M$5.0M$4.0M$0$0$0$10.0M$20.0M
Receivables$7.0M$18.0M$17.0M$14.0M$12.0M$39.0M$32.0M$2.0M$12.0M$34.0M
Fixed Assets$3.0M$3.0M$3.0M$8.0M$4.0M$3.0M$11.0M$13.0M$13.0M$13.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$80.0M$117.0M$79.0M$99.0M$54.0M$150.0M$107.0M$23.0M$74.0M$22.0M
Other Assets$18.0M$18.0M$18.0M$18.0M$18.0M$17.0M$17.0M$17.0M$17.0M$17.0M
Total Liabilities$147.0M$203.0M$168.0M$188.0M$181.0M$149.0M$169.0M$154.0M$77.0M$90.0M
Current Liabilities$49.0M$62.0M$86.0M$38.0M$36.0M$15.0M$21.0M$56.0M$37.0M$49.0M
Borrowings$1.0M$1.0M$0$116.0M$125.0M$131.0M$145.0M$131.0M$3.0M$2.0M
Other Liabilities$146.0M$203.0M$167.0M$72.0M$56.0M$19.0M$24.0M$23.0M$74.0M$89.0M
Equity$6.0M$0$0$0$0$1.0M$1.0M$1.0M$1.0M$1.0M
Reserves$68.0M$42.0M$85.0M$3.0M$-29.0M$162.0M$78.0M$-21.0M$88.0M$74.0M

For Avadel Pharmaceuticals plc, operating cash flow was positive in 3 of 10 reported years; free cash flow in the latest year was negative at $47.0M; free cash flow was positive in 2 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2015201620172018201920202021202220232024
Operating Cash Flow$84.0M$19.0M$17.0M$-83.0M$-38.0M$-49.0M$-77.0M$-70.0M$-129.0M$-47.0M
Investing Cash Flow$-33.0M$-74.0M$-69.0M$-57.0M$39.0M$-70.0M$57.0M$79.0M$-50.0M$52.0M
Financing Cash Flow$-26.0M$-8.0M$-24.0M$-32.0M$0$0$0$-11.0M$28.0M$7.0M
Net Cash Flow$25.0M$-26.0M$-23.0M$-7.0M$0$62.0M$-21.0M$23.0M$-43.0M$20.0M
Free Cash Flow$83.0M$18.0M$-37.0M$-103.0M$-38.0M$-49.0M$-77.0M$-71.0M$-129.0M$-47.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.66
EV / EBITDA177.56
FCF Yield1.30%
Quick Ratio2.37
Interest Coverage1.12
Return 1Y—
Return 3Y—
Return 5Y—

Avadel Pharmaceuticals plc (AVDL) financials — frequently asked questions

What is Avadel Pharmaceuticals plc's annual revenue?

Avadel Pharmaceuticals plc (AVDL) reported annual revenue of $169.0M in its most recent fiscal year.

What is Avadel Pharmaceuticals plc's net profit?

Avadel Pharmaceuticals plc (AVDL) reported a net loss of $49.0M in its most recent fiscal year.

What is AVDL EV/EBITDA?

Avadel Pharmaceuticals plc's enterprise value to EBITDA (EV/EBITDA) ratio is 177.56.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
AVDL Overview AVDL Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.